Guardant Health, Inc. $GH Shares Bought by Casdin Capital LLC

Casdin Capital LLC grew its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 280.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 380,000 shares of the company’s stock after acquiring an additional 280,000 shares during the period. Guardant Health comprises about 2.4% of Casdin Capital LLC’s holdings, making the stock its 10th largest position. Casdin Capital LLC’s holdings in Guardant Health were worth $38,813,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the fourth quarter worth about $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health during the fourth quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter worth about $35,000. Finally, Parallel Advisors LLC increased its stake in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on GH. The Goldman Sachs Group began coverage on Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 price target for the company. Wolfe Research began coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. BTIG Research set a $160.00 price target on Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, May 27th. Wells Fargo & Company upped their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Finally, Raymond James Financial restated an “outperform” rating and set a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $141.95.

Insider Transactions at Guardant Health

In related news, insider John G. Saia sold 20,000 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. This represents a 30.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the transaction, the director directly owned 11,183 shares of the company’s stock, valued at $1,420,017.34. This represents a 47.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 449,006 shares of company stock valued at $51,148,938 in the last three months. 5.60% of the stock is currently owned by company insiders.

Guardant Health Stock Performance

GH stock opened at $129.11 on Thursday. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $135.00. The firm has a market cap of $17.12 billion, a P/E ratio of -38.09 and a beta of 1.61. The stock has a 50-day simple moving average of $105.69 and a 200-day simple moving average of $102.51.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.